Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #305104 on NorthWest Biotherapeutics Inc (NWBO)
anders2211
09/06/20 9:16 AM
#305109 RE: survivor1x #305104
abeta
09/06/20 9:59 AM
#305113 RE: survivor1x #305104
Merck characterizes the measure, "tissue tumor mutational burden-high," or TMB-H, as tumors with at least 10 mutations per megabase or greater, which would be determined via an FDA-approved test. And Merck, incidentally, is leaning on evidence from the same Keynote-158 study that led to its first tissue-agnostic approval in 2017. Updated evidence from the study last year showed higher response rates to Keytruda for people with TMB-high tumors than others.